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Cost-effectiveness studies (%) 
Conclusions Directions for future research 
• Research has evaluated interventions on one particular stage of the medicines pathway 
• Process outcomes are often used rather than end outcomes (health outcomes, costs) 
• Remains unclear: 
• Which aspect of suboptimal use of medicines is a key driver of costs and health loss 
• Which stage of the medicines pathway is more likely to benefit from intervention 
• Decision analytic modelling of the full medicines pathway 
• To evaluate which  aspects of suboptimal medicines use have the most impact 
• To indicate where an intervention could provide the greatest benefits 
• To estimate the how much to invest in improving the pathway 
